Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome

5-azacytidine (5-aza) is a hypomethylating agent approved for the treatment of high-risk myelodysplastic syndrome (MDS). It is assumed to act by demethylating tumor suppressor genes and via direct cytotoxic effects on malignant cells. In vitro treatment with hypomethylating agents has profound effec...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Sohlberg, Ebba, Pfefferle, Aline, Andersson, Sandra, Baumann, Bettina C., Hellström-Lindberg, Eva, Malmberg, Karl-Johan
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2015
Subjects:
Research Paper: Immunology
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4741444/
https://ncbi.nlm.nih.gov/pubmed/26497557
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items